Baseline and Clinical Characteristics of Participants by Cryptococcal Antigen Status
| Covariable . | Total (n = 197) . | CrAg-Negative (n = 130) . | CrAg-Positive (n = 67) . | P Value . |
|---|---|---|---|---|
| Age, years | 39.0 (32.4–47.1) | 39.1 (33.0–47.8) | 38.7 (31.7–47.1) | .67 |
| Sex | ||||
| ȃMale | 100 (50.8) | 70 (53.9) | 30 (44.8) | .23 |
| ȃFemale | 97 (49.2) | 60 (46.2) | 37 (55.2) | |
| Race | ||||
| ȃBlack | 191 (97.0) | 125 (96.2) | 66 (98.5) | .67 |
| ȃOther | 6 (3.1) | 5 (3.9) | 1 (1.5) | |
| CD4 count, cells/mm3 | 33 (12–61) | 40.5 (16–64) | 27 (7–40) | .003 |
| Plasma CrAg titers | 1:40 (5–320) | Not applicable | 1:40 (5–320) | |
| Baseline blood fungal growth | 5 (2.5) | 0 | 5 (7.5) | .002 |
| Tuberculosis in the past 6 monthsa | 51 (25.9) | 33 (25.4) | 18 (26.9) | .82 |
| Tuberculosis treatment | 29 (14.7) | 18 (13.9) | 11 (16.4) | .63 |
| Antiretroviral therapy prior to enrollment | 29 (14.7) | 13 (10.0) | 16 (23.9) | .01 |
| Vital status at 6 months | ||||
| ȃAlive | 160 (81.2) | 113 (86.9) | 47 (70.2) | .01 |
| ȃDead | 28 (14.2) | 11 (8.5) | 17 (25.4) | |
| ȃUnknown | 9 (4.6) | 6 (4.6) | 3 (4.5) |
| Covariable . | Total (n = 197) . | CrAg-Negative (n = 130) . | CrAg-Positive (n = 67) . | P Value . |
|---|---|---|---|---|
| Age, years | 39.0 (32.4–47.1) | 39.1 (33.0–47.8) | 38.7 (31.7–47.1) | .67 |
| Sex | ||||
| ȃMale | 100 (50.8) | 70 (53.9) | 30 (44.8) | .23 |
| ȃFemale | 97 (49.2) | 60 (46.2) | 37 (55.2) | |
| Race | ||||
| ȃBlack | 191 (97.0) | 125 (96.2) | 66 (98.5) | .67 |
| ȃOther | 6 (3.1) | 5 (3.9) | 1 (1.5) | |
| CD4 count, cells/mm3 | 33 (12–61) | 40.5 (16–64) | 27 (7–40) | .003 |
| Plasma CrAg titers | 1:40 (5–320) | Not applicable | 1:40 (5–320) | |
| Baseline blood fungal growth | 5 (2.5) | 0 | 5 (7.5) | .002 |
| Tuberculosis in the past 6 monthsa | 51 (25.9) | 33 (25.4) | 18 (26.9) | .82 |
| Tuberculosis treatment | 29 (14.7) | 18 (13.9) | 11 (16.4) | .63 |
| Antiretroviral therapy prior to enrollment | 29 (14.7) | 13 (10.0) | 16 (23.9) | .01 |
| Vital status at 6 months | ||||
| ȃAlive | 160 (81.2) | 113 (86.9) | 47 (70.2) | .01 |
| ȃDead | 28 (14.2) | 11 (8.5) | 17 (25.4) | |
| ȃUnknown | 9 (4.6) | 6 (4.6) | 3 (4.5) |
Categorical variables are summarized with counts; percentages and P values are based on the Fisher exact or χ2 test. Continuous variables are summarized with medians, interquartile ranges, and P values based on Wilcoxon rank sum test. P values < .05 are bolded.
Abbreviations: CrAg, cryptococcal antigen.
Includes pulmonary, disseminated, or extrapulmonary Mycobacterium tuberculosis infection diagnosed within 6 months prior to or on the day of enrollment.
Baseline and Clinical Characteristics of Participants by Cryptococcal Antigen Status
| Covariable . | Total (n = 197) . | CrAg-Negative (n = 130) . | CrAg-Positive (n = 67) . | P Value . |
|---|---|---|---|---|
| Age, years | 39.0 (32.4–47.1) | 39.1 (33.0–47.8) | 38.7 (31.7–47.1) | .67 |
| Sex | ||||
| ȃMale | 100 (50.8) | 70 (53.9) | 30 (44.8) | .23 |
| ȃFemale | 97 (49.2) | 60 (46.2) | 37 (55.2) | |
| Race | ||||
| ȃBlack | 191 (97.0) | 125 (96.2) | 66 (98.5) | .67 |
| ȃOther | 6 (3.1) | 5 (3.9) | 1 (1.5) | |
| CD4 count, cells/mm3 | 33 (12–61) | 40.5 (16–64) | 27 (7–40) | .003 |
| Plasma CrAg titers | 1:40 (5–320) | Not applicable | 1:40 (5–320) | |
| Baseline blood fungal growth | 5 (2.5) | 0 | 5 (7.5) | .002 |
| Tuberculosis in the past 6 monthsa | 51 (25.9) | 33 (25.4) | 18 (26.9) | .82 |
| Tuberculosis treatment | 29 (14.7) | 18 (13.9) | 11 (16.4) | .63 |
| Antiretroviral therapy prior to enrollment | 29 (14.7) | 13 (10.0) | 16 (23.9) | .01 |
| Vital status at 6 months | ||||
| ȃAlive | 160 (81.2) | 113 (86.9) | 47 (70.2) | .01 |
| ȃDead | 28 (14.2) | 11 (8.5) | 17 (25.4) | |
| ȃUnknown | 9 (4.6) | 6 (4.6) | 3 (4.5) |
| Covariable . | Total (n = 197) . | CrAg-Negative (n = 130) . | CrAg-Positive (n = 67) . | P Value . |
|---|---|---|---|---|
| Age, years | 39.0 (32.4–47.1) | 39.1 (33.0–47.8) | 38.7 (31.7–47.1) | .67 |
| Sex | ||||
| ȃMale | 100 (50.8) | 70 (53.9) | 30 (44.8) | .23 |
| ȃFemale | 97 (49.2) | 60 (46.2) | 37 (55.2) | |
| Race | ||||
| ȃBlack | 191 (97.0) | 125 (96.2) | 66 (98.5) | .67 |
| ȃOther | 6 (3.1) | 5 (3.9) | 1 (1.5) | |
| CD4 count, cells/mm3 | 33 (12–61) | 40.5 (16–64) | 27 (7–40) | .003 |
| Plasma CrAg titers | 1:40 (5–320) | Not applicable | 1:40 (5–320) | |
| Baseline blood fungal growth | 5 (2.5) | 0 | 5 (7.5) | .002 |
| Tuberculosis in the past 6 monthsa | 51 (25.9) | 33 (25.4) | 18 (26.9) | .82 |
| Tuberculosis treatment | 29 (14.7) | 18 (13.9) | 11 (16.4) | .63 |
| Antiretroviral therapy prior to enrollment | 29 (14.7) | 13 (10.0) | 16 (23.9) | .01 |
| Vital status at 6 months | ||||
| ȃAlive | 160 (81.2) | 113 (86.9) | 47 (70.2) | .01 |
| ȃDead | 28 (14.2) | 11 (8.5) | 17 (25.4) | |
| ȃUnknown | 9 (4.6) | 6 (4.6) | 3 (4.5) |
Categorical variables are summarized with counts; percentages and P values are based on the Fisher exact or χ2 test. Continuous variables are summarized with medians, interquartile ranges, and P values based on Wilcoxon rank sum test. P values < .05 are bolded.
Abbreviations: CrAg, cryptococcal antigen.
Includes pulmonary, disseminated, or extrapulmonary Mycobacterium tuberculosis infection diagnosed within 6 months prior to or on the day of enrollment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
